Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neurological Devices Panel meeting postponed

This article was originally published in The Gray Sheet

Executive Summary

FDA postpones Oct. 31 meeting of Neurological Devices Advisory Panel to a date yet to be determined. The panel will review clinical data and discuss questions about Neuronetics' NeuroStar TMS system as a potential treatment for depression, says Peter Anastasiou, the company's VP-marketing. CDRH "will further evaluate data relevant to the topic," according to the agency's website...

You may also be interested in...



Neuro advisory panel to meet

FDA reschedules for Jan. 26 a meeting of its Neurological Devices Panel to discuss Neuronetics' NeuroStar TMS system as a potential treatment for major depressive disorder, according to the firm. The meeting originally was scheduled for Oct. 31, but was postponed to allow for further evaluation of data on the topic, according to CDRH (1"The Gray Sheet" Oct. 16, 2006, In Brief)...

QUOTED. 20 February 2020. Steven Raman.

Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.

Novartis Logs Into India With Digital Innovation Hub

Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.

UsernamePublicRestriction

Register

MT024090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel